Synergistic effects of the MTHFR C677T and A1298C polymorphisms on the increased risk of micro- and macro-albuminuria and progression of diabetic nephropathy among Iranians with type 2 diabetes mellitus

Clinical Biochemistry

Volumn 43, Issue 16-17, 2010, Pages 1333-1339

  Rahimi, Mehrali ^a   Hasanvand, Ali ^b   Rahimi, Zohreh ^a,c   Vaisi Raygani, Asad ^d   Mozafari, Hadi ^c   Rezaei, Mansour ^a   Zargooshi, Javad ^a   Najafi, Farid ^a   Shakiba, Ebrahim ^a  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Macroalbuminuria; Microalbuminuria; MTHFR C677T MTHFR A1298C; Type 2 diabetes mellitus; Western Iran

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; IRAN; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

ALBUMINURIA; ALLELES; AMINO ACID SUBSTITUTION; DEMOGRAPHY; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; IRAN; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 77957335780     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.08.019     Document Type: Article

References (30)

1. Teh M.M., Brooks A.P., Li Voon Chong J.S. Methylenetetrahydrofolate reductase gene polymorphism is not related to diabetic nephropathy in Japanese type 2 diabetic patients. Diab Med 2004, 21:1051-1058.
2. Mtiraoui N., Ezzidi I., Chaieb M., Marmouche H., Aouni Z., Chaieb A., et al. MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. Diab Res Clin Pract 2007, 75:99-106.
3. Maeda M., Yamamoto I., Fukuda M., Motomura T., Nishida M., Nonen Sh., et al. MTHFR gene polymorphism is susceptible to diabetic retinopathy but not to diabetic nephropathy in Japanese type 2 diabetic patients. J Diab Complications 2008, 22:119-125.
4. Moczulski D., Fojcik H., Zukowska-Szczechowska E., Szydlowska I., Grzeszczak W. Effects of the C677T and A1298C polymorphisms of the MTHFR gene on the genetic predisposition for diabetic nephropathy. Nephrol Dial Transplant 2003, 18:1535-1540.
5. Eroglu Z., Erdogan M., Tetik A., Karadeniz M., Cetinalp S., Kosova B., et al. The relationship of the methylenetetrahydrofolate reductase C677T gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diab Metab Res Rev 2007, 23:621-624.
6. Shpichinetsky V., Raz I., Friedlander Y., Goldschmidt N., Wexler I.D., Ben-Yehuda A., et al. The Association between two common mutations C677T and A1298C in human methylenetetrahydrofolate reductase gene and the risk for diabetic nephropathy in type II diabetic patients. J Nutr 2000, 130:2493-2497.
7. Sun J., Xu Y., Zhu Y., Lu H. Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients. J Diab Complications 2004, 64:185-190.
8. Zintzaras E., Uhlig K., Koukoulis G.N., Papathanasiou A.A., Stefanidis I. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy: a meta-analysis. J Hum Genet 2007, 52:881-890.
9. Ukinc K., Ersoz H.O., Karahan C., Erem C., Eminagaoglu S., Hacihasanoglu A.B., et al. Methylenetetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia as a novel risk factor for diabetic nephropathy. Endocrine 2009, 36:255-261.
10. Bluthner M., Bruntgens A., Schmidt S., Strojek K., Grzeszczak W., Ritz E. Association of methylenetetrahydrofolate reductase polymorphism and diabetic nephropathy in type 2 diabetes. Nephrol Dial Transplant 1999, 14:56-57.
11. Rahimi Z., Merat A., Gerard N., Krishnamoorthy R., Nagel R.L. Implications of the genetic epidemiology of globin haplotypes linked to the sickle gene in Southern Iran. Hum Biol 2006, 78:719-731.
12. Azimi-Nezhad M., Ghayour-Mobarhan M., Parizadeh MR, Safarian M, Esmaeili H, Parizadeh SMJ, et al. Prevalence of type 2 diabetes mellitus in Iran and its relationship with gender, urbanisation, education, marital status and occupation. Singapore Med J 2008, 49:571-576.
13. Rahimi Z., Ghaderi M., Nagel R.L., Muniz A. Prevalence of thrombotic risk factors among β-thalassemia patients from Western Iran. J Thromb Thrombolysis 2008, 26:229-233.
14. Rahimi Z., Nomani H., Mozafari H., Vaisi-Raygani A., Madani H., Malek-Khosravi Sh., et al. Factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase C677T polymorphism are not associated with coronary artery disease and type 2 diabetes mellitus in Western Iran. Blood Coagul Fibrinolysis 2009, 20:252-256.
15. Ueland P.M., Hustad S., Schneede J., Refsum H., Vollset S.E. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001, 22:195-201.
16. Russo GT, Di Benedetto A, Magazzu D, Giandalia A, Giorda CB, Ientile R, et al. Mild hyperhomocysteinemia, C677T polymorphism on methylenetetrahydrofolate reductase gene and the risk of macroangiopathy in type 2 diabetes: a prospective study. Acta Diabetol. in press.
17. Hasegawa G., Obayashi H., Kamiuchi K., Nakai M., Kanatsuna T., Yamaguchi M., et al. The association between end-stage diabetic nephropathy and methylenetetrahydrofolate reductase genotype with macroangiopathy in type 2 diabetes mellitus. Exp Clin Endocrinol Diab 2003, 111:132-138.
18. Kerkeni M., Letaief A., Achour A., Miled A., Trivin F., Maaroufi K. Endothelial nitric oxide synthetase, methylenetetrahydrofolate reductase polymorphisms, and cardiovascular complications in Tunisian patients with nondiabetic renal disease. Clin Biochem 2009, 42:958-964.
19. American Diabetes Association Nephropathy in diabetes. Diab Care 2004, 27:S79-S83.
20. WHO Study Group Report of a WHO consultation: Part 1. Diagnosis and classification of diabetes mellitus 1999, World Health Organization, Geneva.
21. Old J.M., Higgs D.R. Gene analysis. Methods in Hemotology. Vol:6. The thalassemias 1983, 74-101. Livingstone. D.J. Weatherall (Ed.).
22. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995, 10:111-113.
23. Vaisi-Raygani A., Rahimi Z., Tavilani H., Pourmotabbed T. Butyrylcholinesterase K variant and the APOE-e4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients. Mol Biol Rep 2010, 37:2083-2091.
24. Neugebauer S., Baba T., Watanabe T. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in NIDDM patients. Lancet 1998, 352:454.
25. Noiri E., Taguchi J.I., Nakao A., Fujita T. MTHFR gene polymorphism as an exacerbation factor of diabetic nephropathy in type 2 diabetes. Analysis in Japanese male hemodialysis patients. Diab Care 2000, 23:260.
26. Nemr R., Salman R.A., Jawad L.H., Juma E.A., Keleshian S.H., Almawi W.Y. Differential contribution of MTHFR C677T variant to the risk of diabetic nephropathy in Lebenese and Bahraini Arabs. Clin Chem Lab Med 2010, 48:1091-1094.
27. Yoshioka K., Yoshida T., Umekawat T., Kogure A., Takakurat H., Toda H., et al. Methylenetetrahydrofolate reductase gene polymorphism is not related to diabetic nephropathy in Japanese type 2 diabetic patients. Diab Med 2004, 21:1051-1058.
28. Boger C.A., Stubanus M., Haak T., Gotz A.K., Christ J., Hoffmann U., et al. Effect of MTHFR C677T genotype on survival in type 2 diabetes patients with end-stage diabetic nephropathy. Nephrol Dial Transplant 2007, 22:154-162.
29. Buysschaert M., Dramais A.S., Wallemacq P.E., Hermans M.P. Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diab Care 2000, 23:1816-1822.
30. Vaccaro O., Pema A.F., Mancini F.P., Cuomo V., Sacco M., Tufano A., et al. Plasma homocystein and its determinants in diabetic retinopathy. Diab Care 2000, 23:1026-1027.